Ascentage Pharma Group International
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | -17.5% | +7.6% | +113.2% | -14.2% | +124.2% | +651.4% | +5.9% | +341.8% | -43.1% | |
| – | – | – | – | -6.2% | +69.3% | +561.0% | +38.8% | -4.8% | +352.9% | |
| – | -14.6% | +7.6% | +82.4% | -15.6% | +134.5% | +663.6% | +2.0% | +397.1% | -55.2% | |
| – | +15.7% | +110.0% | +85.9% | +21.7% | +35.8% | -3.1% | -4.9% | +34.0% | +14.4% | |
| – | -24.3% | +565.6% | +10.8% | -36.6% | +128.9% | +18.9% | +6.1% | +3.3% | +220.6% | |
| – | +12.3% | +143.3% | +78.5% | +13.3% | +42.0% | +8.3% | +2.6% | +24.2% | +21.5% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | +1,677.8% | -36.3% | -88.4% | +46.4% | +167.5% | +215.5% | +82.0% | -32.9% | -18.4% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -2,408.9% | – | – | – | -35.2% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.